PCM
TPST icon

Portolan Capital Management’s Tempest Therapeutics TPST Stock Holding History

Portolan Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-227
Closed -$1.02M – 139
2016
Q4 		$1.02M Sell
227
-68
-23% -$847K 0.14% 116
2016
Q3 		$6.18M Buy
295
+158
+115% +$2.86M 0.85% 45
2016
Q2 		$2.09M Buy
137
+3
+2% +$68.5K 0.3% 94
2016
Q1 		$3.72M Buy
+134
New +$2.83M 0.5% 72

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Portolan Capital Management's TPST Position: Q1 2017 in Review

Portolan Capital Management sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 227 shares — an estimated $1.02M sold.

Portolan Capital Management first reported a position in TPST in Q1 2016 and held it in 4 quarters. The position peaked at $6.18M in Q3 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

  • Portolan Capital Management reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Portolan Capital Management sold 227 Tempest Therapeutics shares in Q1 2017, an estimated $1.02M.
  • Portolan Capital Management first reported a position in Tempest Therapeutics in Q1 2016 and held it in 4 quarters.
  • Portolan Capital Management's Tempest Therapeutics position peaked at $6.18M in Q3 2016.
  • 63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on Portolan Capital Management's 13F filing for Q1 2017, filed 15 May 2017.